Publications
68
Citations
1,023
Est. group size
~8
Recurring co-author estimate
Active years
18
Publishing since 2009
Typically publishes in teams of ~13 · 3% small-team papers (≤3 authors) · across 11 venues
- Abstract 6736: Discovery and characterization of BH-501284: A non-covalent, pan-KRAS inhibitor for treatment of diverse <i>KRAS</i> -mutant tumors.
Cancer Research · 2026
- Abstract 5120: Design and discovery of BH-501242, a novel pan-KRAS on/off inhibitor targeting KRAS switch II pocket
Cancer Research · 2026
- Abstract 5608: Design and discovery of BH-30643: A novel, reversible, mutant-selective macrocyclic EGFR inhibitor invulnerable to common resistance mutations
Cancer Research · 2025
- Abstract 5944: Discovery of BH-30236: A novel macrocyclic CLK inhibitor targeting alternative splicing in cancers
Cancer Research · 2024
- BH-30236, a Novel Macrocyclic Clk Inhibitor Modulating Aberrant RNA Splicing, Demonstrates Potent Anti-Cancer Activity Against Myeloid Malignancies
Blood · 2024
- Supplementary Data from Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
2023
- Supplementary Data from Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
2023
- Computational Analysis of the Neurophysiological Effects of Spinal Cord Stimulation
Deep Blue (University of Michigan) · 2023
- Data from Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
2023
- Data from Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations
2023
- TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations
Molecular Cancer Therapeutics · 2021
- Abstract 1469: TPX-0131, a potent inhibitor of wild type ALK and a broad spectrum of both single and compound ALK resistance mutations
Cancer Research · 2021
- Abstract 1119: Molecular characteristics of repotrectinib that enable potent inhibition of TRK fusion proteins and broad mutant selectivity
Cancer Research · 2021
- Crystal structure of TrkA (G595R) kinase domain
2021
- Crystal structure of TrkA kinase with repotrectinib
2021
- Cancer Research×16
- Neuromodulation Technology at the Neural Interface×10
- Molecular Cancer Therapeutics×4
- Journal of Neural Engineering×3
- Experimental and Molecular Therapeutics×3
- Jaimin K. Rana
Medicine · University of Michigan
- Ai Ni
Medicine · The Ohio State University
- Angel Qin
Medicine · University of Michigan
- Alexander Cooke
Medicine · University of Michigan
- Bryan J. Schneider
Medicine · University of Michigan
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile